Consensus Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/07/2026 BST			5-day change	1st Jan Change
21.98 ^USD	-4.60%		-5.46%	+40.18%

06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI

Evolution of the Average Target: Monte Rosa Therapeutics, Inc.

Evolution of the Target Price: Monte Rosa Therapeutics, Inc.

Changes in Analyst Recommendations: Monte Rosa Therapeutics, Inc.

145c1cdce649aa7aadd18bab3734b954._8DaeAvlMKOkl9Y4IF2Ti-36EhhN5yPW8jWri046JyI.qYWACUOXVdXBwedQT2vL-7WQQyA4tUKFiEHv5TRWVGGpjbcvUpd-x8rNnw~308914a47fc4d081fa542b3cdafbc3eb

Analysts' recommendations: Monte Rosa Therapeutics, Inc.

12-16	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating	MT
12-16	Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13	MT
15/09/25	Wedbush Raises Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Outperform Rating	MT
21/03/25	Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating	MT
19/12/24	Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14	MT
28/10/24	Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating	MT
29/04/24	UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating	MT
15/02/24	Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target	MT
17/03/23	Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating	MT
03/01/23	Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18	MT
13/10/22	UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target	MT
15/08/22	Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target	MT
12/05/22	Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating	MT
28/04/22	Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target	MT
30/03/22	Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating	MT
10/02/22	Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target	MT
03/01/22	Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating	MT
17/11/21	Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target	MT
14/10/21	MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating	MT
19/07/21	MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MONTE ROSA THERAPEUTICS, INC.					+43.95%
	LONZA GROUP AG					+14.2%
	REVOLUTION MEDICINES, INC.					+7.17%
	IQVIA HOLDINGS INC.					+10.48%
	BEONE MEDICINES AG					+38.69%
	CELLTRION, INC.					+46.5%
	ASCENDIS PHARMA A/S					+9.89%
	MEDPACE HOLDINGS, INC.					-16.13%
	EUROFINS SCIENTIFIC SE					+3%
	ICON PUBLIC LIMITED COMPANY					+7.81%
	Average					+16.56%
	Weighted average by Cap.					+16.44%